Location Directory

Clinical trials in Orlando, Florida

This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

6860

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions: Maridebart Cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 31
States / cities: Gilbert, Arizona • Canoga Park, California • Cerritos, California + 26 more

Conditions: Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
Interventions: Biospecimen Collection, Compliance Monitoring, Health Promotion and Education, Informational Intervention, Media Intervention, Medical Device Usage and Evaluation, Mercaptopurine, Questionnaire Administration, Telephone-Based Intervention, Training and Education; Procedure · Behavioral · Other + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 10 Years to 25 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 27
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 20 more

Conditions: Obesity, Overweight
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 71
States / cities: Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 57 more

Conditions: HIV-1 Infection
Interventions: DOR/ISL, BIC/FTC/TAF, Placebo to DOR/ISL, Placebo to BIC/FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 38
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 29 more

Conditions: HIV Infections
Interventions: CAB LA, New formulation of CAB LA; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 16 Years and older
Enrollment: 229 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 19 more

Conditions: Glioblastoma Multiforme
Interventions: Optune®; Device
Lead sponsor: NovoCure Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 981 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 86
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 67 more

Conditions: Renal Impairment
Interventions: Sulthiame; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Altamonte Springs, Florida • Miami Lakes, Florida

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: 100mg SPN-812, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 48 Months to 69 Months
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 54
States / cities: Saraland, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 49 more

Conditions: Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Urothelial Cancer
Interventions: AVZO-103, Combination Agent; Drug
Lead sponsor: Avenzo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 15
States / cities: San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 12 more

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Litifilimab, Litifilimab-matching placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 38
States / cities: Phoenix, Arizona • Beverly Hills, California • Huntington Beach, California + 34 more

Conditions: Gastrointestinal Neoplasms
Interventions: IDRX-42, Sunitinib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 49
States / cities: Phoenix, Arizona • Duarte, California • La Jolla, California + 42 more

Conditions: Hypercholesterolaemia
Interventions: laroprovstat/rosuvastatin 1, laroprovstat/rosuvastatin 2, laroprovstat/rosuvastatin 3, laroprovstat/rosuvastatin 4, Placebo to match laroprovstat/rosuvastatin 1,2,3, Placebo to match laroprovstat/rosuvastatin 4, Rosuvastatin 1, Rosuvastatin 2, Rosuvastatin 3, Rosuvastatin 4, Placebo to match Rosuvastatin; Combination Product · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Sun City West, Arizona • Gardena, California • Lomita, California + 22 more

Clinical trials in Orlando, Florida

Filter and sort this location

Live official records

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia